Business
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
NDA to be Submitted on a Rolling Basis, Beginning Early 2026PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead product candidate for the prevention of surgical
About this update from Polypid Ltd.
[{"type":"image","alt":"PolyPid Ltd.","displaySize":"","headline":null,"caption":"PolyPid Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/fdc21f8c528080a8e08cb717b24cf2fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p.GVrjAO9AQ10s3m1PTgIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fdc21f8c528080a8e08cb717b24cf2fd","width":300,"height":140}},"lazy":false},{"type":"text","content":"NDA to be Submitted on a Rolling Basis, Beginning Early 2026","length":60,"tagName":"p"},{"type":"text","content":"PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries.","length":490,"tagName":"p"},{"type":"text","content":"The FDA agreed that the Company’s existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a rolling NDA review, allowing PolyPid to submit the first completed sections in early 2026.","length":288,"tagName":"p"},{"type":"text","content":"Based on the FDA’s Pre-NDA meeting written response, the Company concludes that the objectives of the pre-NDA meeting have been accomplished and has determined that the in-person meeting, originally scheduled for December 3, 2025, is no longer necessary.","length":254,"tagName":"p"},{"type":"text","content":""We are pleased with the pre-NDA meeting feedback we received from the FDA, which confirmed agreement on the content and format for our planned NDA submission, and appreciate the agency's collaborative engagement throughout this process," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "The agreement on the adequacy of the clinical data package for submission, combined with our Breakthrough Therapy designation, validates our regulatory strategy and keeps us firmly on track to bring this potential...